Crizotinib-induced esophageal ulceration: A novel adverse event of crizotinib-Reference-Cited by-同舟云学术

Crizotinib-induced esophageal ulceration: A novel adverse event of crizotinib

Published:2013-09 Issue:3 Volume:81 Page:495-496
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Park Jangchul,Yoshida Kimihide,Kondo Chiaki,Shimizu Junichi,Horio Yoshitsugu,Hijioka Susumu,Hida Toyoaki

Funder

National Cancer Center Research and Development Funds

Health and Labour Sciences Research Grants for Clinical Research for Evidence-Based Medicine from the Ministry of Health, Labour, and Welfare of Japan

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference4 articles.

1. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

2. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

3. Drug-induced esophagitis;Zografos;Dis Esophagus,2009

4. Oesophageal transit of six commonly used tablets and capsules;Hey;Br Med J,1982

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS);International Journal of Clinical Pharmacy;2022-07-01

2. Medication‐Induced Esophageal Injury;The Esophagus;2021-04-30

3. Severe ulcerative esophagitis and colitis induced by crizotinib therapy: A case report;Advances in Digestive Medicine;2020-11-22

4. Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient;Molecular and Clinical Oncology;2018-01-11

5. A case of crizotinib-induced esophageal ulcers;Lung Cancer Management;2017-07